Načítá se...
Switching treatments in haemophilia: is there a risk of inhibitor development?
Patients with haemophilia A (and their physicians) may be reluctant to switch factor VIII (FVIII) concentrates, often due to concerns about increasing the risk of inhibitors; this reluctance to switch may contribute to patients missing the clinical benefits provided by the arrival of new factor VIII...
Uloženo v:
| Vydáno v: | Eur J Haematol |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BlackWell Publishing Ltd
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4407931/ https://ncbi.nlm.nih.gov/pubmed/25135593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.12433 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|